PerkinElmer expands informatics capabilities in biologics drug discovery

Biotechnology company PerkinElmer has announced its documentation, workflow and decision-making informatics platform, Signals, is expanding to build on existing capabilities in the biologics drug discovery space. This comes through a collaboration with Insightful Science, a software company serving the global life sciences community.

With the collaboration, pharmaceutical and academic research teams can combine the power of the Signals platform with solutions from Insightful Science’s Bioinformatics division. This includes SnapGene and Geneious Prime software offerings that enable molecular biologists design and execute DNA construct design, molecular cloning and other kinds of molecular biology research.

The integration will give scientists the ability to access and compare data across experiments and instruments, and collaborate more intuitively. They can also replicate assays and experiments instantly, leading to faster time-to-result and more informed decision making on drug and vaccine targets.

Kevin Willoe, VP and GM of PerkinElmer, Informatics, said: “Through our collaboration with Insightful Science, we’re able to provide enhanced informatics capabilities to scientists doing vital biologics and vaccine research. This will help significantly reduce cycle times for researchers and aid them in making data-driven decisions faster and more accurately – important capabilities when fighting foes like cancer, cardio, neurological and viral diseases.”

Brett Ammundsen, CEO Bioinformatics at Insightful Science, said: “The combination of SnapGene and Geneious Prime software with the PerkinElmer Signals platform powerfully enhances research workflows and enriches collaboration. Ultimately this will better connect scientists to their ideas and data, so they can focus o

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free